A. Randomized Controlled Trials (n=8)

B. Non-randomized Controlled Trials / Before-after studies (n=59)

Supplementary Figure 2: Risk of bias of the experimental studies included in the immunogenicity analysis

a. Representativeness based on the description of the source population, the representativeness of the eligible population, the inclusion criteria and the percentage of participation.
b. Selection of the compared groups from the same source and the response rate.
c. Blinding of study participants and personnel or no impact on the results
d. Comparability of administered vaccine, time since vaccination, risk of exposure to measles, malnutrition and no control for maternal antibodies.
e. Completeness of outcome data.
f. Information bias assessment based on same vaccine strain and potency administered to all participants and laboratory method to detect antibodies.
g. Possibility of selective outcome reporting.